Conditions: Cytomegalovirus Infections
Keywords: cytomegalovirus CMV prophylaxis liver liver transplant
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 307
Healthy volunteers: no

Brief summary:
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant.

Detailed description:
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and efficacy of maribavir for the prevention of CMV disease when given as prophylaxis for up to 14 weeks following orthotopic liver transplantation.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: maribavir intervention 2: ganciclovir
Intervention descriptions: intervention 1: 100mg twice a day for 14 weeks. intervention 2: 1000mg three times per day for 14 weeks.

Protocol document: